Cytokinetics CYTK
NASDAQ CYTK
$55.38 +0.24 (+0.43%)
As of: Nov 10, 2026 · 1:13 PM EST

Cytokinetics (CYTK) Cash from Restructuring (2012)

Updated

Cytokinetics (CYTK) recorded Cash from Restructuring of -$112,000 in Q4 2012.

Analysis

Cytokinetics (CYTK) Cash from Restructuring (2012) Analysis & Trends

For FY2012, Cytokinetics reported Cash from Restructuring of -$56,000.

  • Across earlier years, Cash from Restructuring came in at $194,000 in FY2011 and $22,000 in FY2009.
  • Per Business Quant, the preceding three quarters came in at $110,000 (Q3 2012), -$13,000 (Q2 2012) and -$41,000 (Q1 2012).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Cytokinetics 7.81 Bn 3.81 Bn 47.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 -112,000.00
Sep 30, 2012 110,000.00
Jun 30, 2012 -13,000.00
Mar 31, 2012 -41,000.00
API Access

Cytokinetics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=CYTK&period=max&api_key=YOUR_API_KEY